Somatic inactivating variants in the gene CDK12, encoding cyclin-dependent kinase 12, generate fusion-induced neoantigens in prostate cancer. This finding supports the hypothesis that prostate cancers with variant CDK12 will have a response to checkpoint inhibitor drugs.
The New England journal of medicine. 2018 Sep 13 [Epub]
Emmanuel S Antonarakis
From the Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore.